Key result
Complete tumor resection and FNCLCC grade independently predict progression-free survival in recurrent retroperitoneal leiomyosarcoma.
Why the study?
What are the independent prognostic factors for progression-free survival in patients with recurrent or metastatic retroperitoneal leiomyosarcoma?
Cohort (n=22)
What are the independent prognostic factors for progression-free survival in patients with recurrent or metastatic retroperitoneal leiomyosarcoma?
Complete resection and FNCLCC disease grade are independent predictors of progression-free survival in patients with recurrent or metastatic retroperitoneal leiomyosarcoma.
Median PFS of 9 months signals guarded outlook in this rare disease; Level 4 data leave prognostic factors open for validation in larger cohorts.
AIMS: Factors that predict the prognosis of patients with recurrent or metastatic retroperitoneal leiomyosarcomas after treatment are uncertain. MATERIALS & METHODS: Clinical and pathological data on 22 patients with retroperitoneal leiomyosarcomas who were treated by a multidisciplinary abdominal soft-tissue tumor group were analyzed retrospectively to identify prognostic factors for their progression-free survival (PFS). RESULTS & CONCLUSION: The median PFS in the 22 patients was 9 months. Microvessel density in tumor tissues, which was evaluated via CD34 expression in 16 cases, and the presence of metastasis on admission were both found to be correlated with PFS in a Kaplan-Meier analysis, but not in a multivariate analysis. The multivariate analysis did, however, show that complete resection of tumors and the FNCLCC (Fédération Nationale des Centres de Lutte Contre Le Cancer) disease grade were independent factors predicting PFS.
No takes yet. Share an insight, caveat, or question.
Li et al. (2015) conducted a cohort in recurrent or metastatic retroperitoneal leiomyosarcoma (n=22). Prognostic factors (complete resection, FNCLCC disease grade) was evaluated on Progression-free survival (PFS). Complete resection of tumors and FNCLCC disease grade were independent factors predicting progression-free survival (median 9 months) in recurrent or metastatic retroperitoneal leiomyosarcoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: